Hyman IP Law

About Laurence J. Hyman

Laurence J. (Larry) Hyman focuses his practice on biotechnology patenting, strategic planning and counseling, technology licensing, intellectual property due diligence, patent portfolio evaluations, and portfolio management. Mr. Hyman also advises clients on compliance with reporting requirements for research conducted under federal funding. Mr. Hyman has represented a wide variety of clients, including the U.S. Government, universities and research institutes, start-up and medium sized biotechnology companies, venture capital groups, and pharmaceutical companies. Mr. Hyman has served since 2011 as a reviewer of grant applications on therapeutics, diagnostics, and medical devices for the University of California, San Francisco, Clinical and Translational Science Institute (“CTSI”) and was recognized in 2015 as an “Outstanding Advisor” for his contributions to CTSI’s Catalyst Awards Program. Mr. Hyman also serves as a reviewer of applicants to the California Life Sciences Association’s “FAST” Advisory Program for start-ups. Mr. Hyman was recognized as a 2011 “Top Patent Prosecutor for Pharmaceuticals-Biotechnology” by the patent analytics website PatentBuddy.com.

Mr. Hyman’s patent and licensing work has encompassed biologics (including antibody therapeutics and antibody-drug conjugates), protein chemistry, nanoparticles, liposomes, biochemistry, molecular biology, glycobiology, RNA interference, immunology, human and animal vaccines, tissue engineering, plant biology, agricultural methods and compositions, transgenic animals, plants and bacteria, biofuels, personalized medicine, enzymology, nanotechnology, stem cells, food coatings and processing, drug administration, high throughput screening, water purification, imaging methods, radiation administration, and microfluidic and medical devices. A number of the patents and applications he has written on inventions by universities and research institutions have been licensed by pharma companies and have supported investments in clinical development of the inventions.

Before founding HYMAN IP LAW, Mr. Hyman was a partner at Townsend and Townsend and Crew LLP, a national, IP-focused firm (now part of Kilpatrick Townsend & Stockton LLP). Prior to entering private practice, Mr. Hyman served in the National Institutes of Health’s Office of Technology Transfer, where he was the lead patent advisor for the General Medicine Workgroup. He is a member of the bars of California, New York and Massachusetts (currently voluntarily on inactive status in MA) and is a registered patent attorney. 

In addition to his practice at HYMAN IP LAW, Mr. Hyman is of counsel to the law firm canady + lortz LLP.